Faberge Fertility

Executive Summary

Faberge Fertility is a pre-clinical medical device startup developing the Precision ETS, a patent-pending embryo transplant system designed to improve IVF outcomes by increasing pregnancy rates and reducing ectopic pregnancies. Founded in 2020 and headquartered in New York, the company addresses a critical unmet need in reproductive health: the high failure rate of embryo transfers, which contributes to emotional and financial burden on patients. The Precision ETS aims to enhance the precision and safety of the transfer process, potentially setting a new standard in fertility care. As the global IVF market continues to expand, driven by rising infertility rates and delayed childbearing, Faberge Fertility's innovative solution could capture significant market share if successfully commercialized. Currently in the pre-clinical stage without FDA clearance, the company faces typical early-stage risks including regulatory hurdles, clinical validation, and funding requirements. However, the strong scientific rationale and clear value proposition provide a foundation for future growth. The company's progress will depend on successful completion of preclinical studies, FDA interactions, and securing partnerships or financing for clinical trials. While the technology is promising, investors should monitor key milestones such as first-in-human study initiation and regulatory submissions.

Upcoming Catalysts (preview)

• Q2 2027Initiation of First-in-Human Clinical Study40% success
• Q4 2026FDA Investigational Device Exemption (IDE) Submission50% success
• Q1 2027Series A Funding or Strategic Partnership Announcement45% success